UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety

European respiratory review, 2020-03, Vol.29 (155), p.190151

2020

Volltextzugriff (PDF)

The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma

Allergy (Copenhagen), 2020-04, Vol.75 (4), p.761-768

2020

Volltextzugriff (PDF)

The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation

Respiratory research, 2018-09, Vol.19 (1), p.189-189, Article 189

2018

Volltextzugriff (PDF)

Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.1507-1514

2018

Volltextzugriff (PDF)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

International journal of chronic obstructive pulmonary disease, 2017-01, Vol.12, p.907-922

2017

Volltextzugriff (PDF)

Considerations for managing chronic obstructive pulmonary disease in the elderly

Clinical interventions in aging, 2014-01, Vol.9, p.23-30

2014

Volltextzugriff (PDF)

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

BMC pulmonary medicine, 2018-06, Vol.18 (1), p.100-100, Article 100

2018

Volltextzugriff (PDF)

Optimizing identification and management of COPD patients – reviewing the role of the community pharmacist

British journal of clinical pharmacology, 2017-01, Vol.83 (1), p.192-201

2017

Volltextzugriff (PDF)

The rationale for development of ligelizumab in food allergy

The World Allergy Organization journal, 2022-09, Vol.15 (9), p.100690-100690, Article 100690

2022

Volltextzugriff (PDF)

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation

Respiratory medicine, 2014-09, Vol.108 (9), p.1310-1320

2014

Volltextzugriff (PDF)

Addressing unmet needs in the treatment of COPD

European respiratory review, 2014-09, Vol.23 (133), p.333-344

2014

Volltextzugriff (PDF)

Evaluation of Glycopyrronium Therapy in Chinese Patients Versus Predominantly Caucasian Populations in Patients With Moderate-to-Severe COPD: Comparison of Clinical Data

Chest, 2016-04, Vol.149 (4), p.A390-A390

2016

Volltextzugriff (PDF)

Treatment With Formoterol Fumarate Inhalation Solution (FFIS) Among COPD Patients With High Use of Nebulized Short Acting Beta 2-Agonists (SABAs

Chest, 2012-10, Vol.142 (4), p.657A-657B

2012

Volltextzugriff (PDF)

The prostaglandin D 2 receptor 2 pathway in asthma: a key player in airway inflammation

Respiratory research, 2018-09, Vol.19 (1), p.189

2018

Volltextzugriff (PDF)

The impact of the prostaglandin D 2 receptor 2 and its downstream effects on the pathophysiology of asthma

Allergy (Copenhagen), 2020-04, Vol.75 (4), p.761-768

2020

Volltextzugriff (PDF)

Uncontrolled asthma across GINA treatment steps 2 − 5 in a large US patient cohort

The Journal of asthma, 2022-05, Vol.59 (5), p.1051-1062

2022

Volltextzugriff (PDF)

Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)

Journal of allergy and clinical immunology, 2022-05, Vol.149 (5), p.1675-1682.e3

2022

Volltextzugriff (PDF)

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD

The European respiratory journal, 2014-12, Vol.44 (6), p.1548-1556

2014

Volltextzugriff (PDF)

Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond

The European respiratory journal, 2023-04, Vol.61 (4), p.2201307

2023

Volltextzugriff (PDF)

Development of an inhaled anti-TSLP therapy for asthma

Pulmonary pharmacology & therapeutics, 2023-02, Vol.78, p.102184-102184, Article 102184

2023

Volltextzugriff (PDF)

The pharmacology of the prostaglandin D 2 receptor 2 (DP 2 ) receptor antagonist, fevipiprant

Pulmonary pharmacology & therapeutics, 2021-06, Vol.68, p.102030

2021

Volltextzugriff (PDF)

The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant

Pulmonary pharmacology & therapeutics, 2021-06, Vol.68, p.102030, Article 102030

2021

Volltextzugriff (PDF)

Potential systemic effects of acquired CFTR dysfunction in COPD

Respiratory medicine, 2024-01, Vol.221, p.107499, Article 107499

2024

Volltextzugriff (PDF)

Patient perception of Breezhaler® and Ellipta® device feedback mechanisms in COPD: The ADVANTAGE Study

Current medical research and opinion, 2019-02, Vol.35 (2), p.221-227

2019

Volltextzugriff (PDF)

Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database

Chronic obstructive pulmonary diseases, 2024-01, Vol.11 (5), p.472-481

2024

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(60)
Humans
(50)
Female
(23)
Respiratory System
(18)
General & Internal Medicine
(15)
Male
(14)
Medicine, General & Internal
(13)
Medicine
(12)
Middle Aged
(12)
Mortality
(12)
Treatment Outcome
(12)
Adult
(11)
Aged
(11)
Patients
(11)
Risk Factors
(11)
Clinical Trials
(10)
Medical Research
(10)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(10)
Studies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety

The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma

The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation

Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

Considerations for managing chronic obstructive pulmonary disease in the elderly

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

Optimizing identification and management of COPD patients – reviewing the role of the community pharmacist

The rationale for development of ligelizumab in food allergy

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation

Addressing unmet needs in the treatment of COPD

Evaluation of Glycopyrronium Therapy in Chinese Patients Versus Predominantly Caucasian Populations in Patients With Moderate-to-Severe COPD: Comparison of Clinical Data

Treatment With Formoterol Fumarate Inhalation Solution (FFIS) Among COPD Patients With High Use of Nebulized Short Acting Beta 2-Agonists (SABAs

The prostaglandin D 2 receptor 2 pathway in asthma: a key player in airway inflammation

The impact of the prostaglandin D 2 receptor 2 and its downstream effects on the pathophysiology of asthma

Uncontrolled asthma across GINA treatment steps 2 − 5 in a large US patient cohort

Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD

Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond

Development of an inhaled anti-TSLP therapy for asthma

The pharmacology of the prostaglandin D 2 receptor 2 (DP 2 ) receptor antagonist, fevipiprant

The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant

Potential systemic effects of acquired CFTR dysfunction in COPD

Patient perception of Breezhaler® and Ellipta® device feedback mechanisms in COPD: The ADVANTAGE Study

Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database

Suchergebnisse filtern